Anagenics Ltd has released a press release.
USA launch of evolis
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Anagenics
- Cellmid: Appendix 3Y- Change of Director’s Interest Notice
- ASX Market Release - Reinstatement
- Cellmid records highest ever quarterly sales for evolis
- Midkine Antibodies Show Anti-Tumor Activity In Brain Cancer
- European Midkine Patent For Surgical Adhesion Allowed
Later from Anagenics
- Cellmid receives 831K R&D tax credit
- Cellmid Updates on CxBladder License
- Cellmid receives australian govt grant for midkine programme
- Appendix 4C
- Cellmids usa midkine patent for alopecia allowed
Follow Anagenics into a list and get an email when it puts out news.
Follow Anagenics